Phase I trial of selenium plus chemotherapy in gynecologic cancers

Mihae Song, Muthu N. Kumaran, Murugesan Gounder, Darlene G. Gibbon, Wilberto Nieves-Neira, Ami Vaidya, Mira Hellmann, Michael P. Kane, Brian Buckley, Weichung Shih, Paula B. Caffrey, Gerald D. Frenkel, Lorna Rodriguez-Rodriguez

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Purpose: Preclinical studies performed in our laboratory have shown that high-dose selenium inhibits the development of carboplatin drug resistance in an ovarian cancer mouse xenograft model. Based on these data, as well as the potential serious toxicities of supranutritional doses of selenium, a phase I trial of a combination of selenium/carboplatin/paclitaxel was designed to determine the maximum tolerated dose, safety, and effects of selenium on carboplatin pharmacokinetics in the treatment of chemo-naive women with gynecologic cancers. Correlative studies were performed to identify gene targets of selenium. Methods: Chemo-naïve patients with gynecologic malignancy received selenious acid IV on day 1 followed by carboplatin IV and paclitaxel IV on day 3. A standard 3 + 3 dose-escalating design was used for addition of selenium to standard dose chemotherapy. Concentrations of selenium in plasma and carboplatin in plasma ultrafiltrate were analyzed. Results: Forty-five patients were enrolled and 291 treatment cycles were administered. Selenium was administered as selenious acid to 9 cohorts of patients with selenium doses ranging from 50 μg to 5000 μg. Grade 3/4 toxicities included neutropenia (66.7%), febrile neutropenia (2.2%), pain (20.0%), infection (13.3%), neurologic (11.1%), and pulmonary adverse effects (11.1%). The maximum tolerated dose of selenium was not reached. Selenium had no effect on carboplatin pharmacokinetics. Correlative studies showed post-treatment downregulation of RAD51AP1, a protein involved in DNA repair, in both cancer cell lines and patient tumors. Conclusion: Overall, the addition of selenium to carboplatin/paclitaxel chemotherapy is safe and well tolerated, and does not alter carboplatin pharmacokinetics. A 5000 μg dose of elemental selenium as selenious acid is suggested as the dose to be evaluated in a phase II trial.

Original languageEnglish (US)
Pages (from-to)478-486
Number of pages9
JournalGynecologic oncology
Volume150
Issue number3
DOIs
StatePublished - Sep 2018

Keywords

  • Carboplatin
  • Chemotherapy
  • Chemotherapy resistance
  • Gynecologic cancer
  • Selenium

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Phase I trial of selenium plus chemotherapy in gynecologic cancers'. Together they form a unique fingerprint.

  • Cite this

    Song, M., Kumaran, M. N., Gounder, M., Gibbon, D. G., Nieves-Neira, W., Vaidya, A., Hellmann, M., Kane, M. P., Buckley, B., Shih, W., Caffrey, P. B., Frenkel, G. D., & Rodriguez-Rodriguez, L. (2018). Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecologic oncology, 150(3), 478-486. https://doi.org/10.1016/j.ygyno.2018.07.001